# Paracetamol in Addition to WHO Step III Opioids in Chronic Cancer Pain Control

> **NCT05088876** · PHASE4 · TERMINATED · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 7 (actual)

## Conditions studied

- Pain

## Interventions

- **DRUG:** Placebo
- **DRUG:** Paracetamol

## Key facts

- **NCT ID:** NCT05088876
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-08-28
- **Primary completion:** 2026-03-05
- **Final completion:** 2026-03-05
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Recruitment difficulties
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05088876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05088876, "Paracetamol in Addition to WHO Step III Opioids in Chronic Cancer Pain Control". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05088876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*